Nucleai

Company Overview

Snapshot

Founded in July 2017 by Avi Veidman, Eliron Amir, and Lotan Chorev, Nucleai operates with 51–200 employees. The company has raised a total of $60.5 million across 4 funding rounds from 11 investors.

Business overview

Nucleai develops a spatial biology software platform for precision medicine, leveraging intelligence-grade geospatial AI methods to analyze and interpret complex cellular interactions in patient biopsies. Its core technology translates these interactions into actionable insights, accelerating the development of life-saving treatments and diagnostics. The platform offers an AI-driven spatial biomarker analysis solution that ingests images from various modalities (H&E, IHC, and multiplex immunofluorescence), performs advanced spatial analysis, and delivers insights to empower pathologists and researchers. Nucleai serves the biopharma, diagnostics, contract research organizations (CROs), and life sciences tools industries, focusing on areas like bi-specifics, antibody-drug conjugates (ADCs), and immunotherapy.

Strategic signal

In June 2024, Nucleai announced a strategic partnership with Proscia to integrate predictive biomarker solutions, alongside news of workforce optimization impacting 15% of its employees. This indicates a dual focus on expanding its technological capabilities through collaboration while simultaneously streamlining operations, signaling a strategic recalibration to enhance efficiency and market reach in the competitive spatial biology sector.

Company Intelligence Q&A

What was a significant recent partnership for Nucleai?

In June 2024, Nucleai partnered with Proscia to integrate predictive biomarker solutions, aiming to enhance the capabilities of both companies in the digital pathology and precision medicine fields.

What recent operational change occurred at Nucleai?

In June 2024, Nucleai implemented workforce optimizations, resulting in a 15% reduction in its employee base.

What was the nature of Nucleai's collaboration with GoPath Diagnostics?

In April 2024, Nucleai and GoPath Diagnostics announced a strategic collaboration to provide integrated AI-powered digital pathology solutions for clinical research and diagnostic applications.

What was the focus of Nucleai's partnership with Lunaphore?

In September 2022, Lunaphore and Nucleai announced a partnership to provide AI-powered spatial biology analysis, aimed at accelerating drug development.